Cytokine derived treatment with reduced vascular leak syndrome

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11401312
APP PUB NO 20160068584A1
SERIAL NO

14785536

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an interleukin 15 (IL-15) derivative conjugate so as to induce a proliferation of natural killer cells (NK cells) which is the same or higher than the one obtained with high dose of interleukin-2 (HDIL-2); eventually associated with a pharmaceutically acceptable carrier.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INSTITUT GUSTAVE ROUSSY94805 VILLEJUIF CÉDEX

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bechard, David Saint-Etienne de Montluc, FR 15 103
Chaput, Nathalie Paris, FR 6 26
Desbois, Melanie Maison Alfort, FR 5 26

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Feb 2, 2026
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 2, 2030
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 2, 2034
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00